Primary Sjö gren's syndrome (SS) shares many features with systemic lupus erythematosus (SLE). Here we investigated the association of the three major polymorphisms in IRF5 and STAT4 found to be associated with SLE, in patients from Sweden and Norway with primary SS. These polymorphisms are a 5-bp CGGGG indel in the promoter of IRF5, the single nucleotide polymorphism (SNP) rs10488631 downstream of IRF5 and the STAT4 SNP rs7582694, which tags the major risk haplotype of STAT4. We observed strong signals for association between all three polymorphisms and primary SS, with odds ratios (ORs) 41.4 and P-values o0.01. We also found a strong additive effect of the three risk alleles of IRF5 and STAT4 with an overall significance between the number of risk alleles and primary SS of P ¼ 2.5 Â 10 À9 . The OR for primary SS increased in an additive manner, with an average increase in OR of 1.78. For carriers of two risk alleles, the OR for primary SS is 1.43, whereas carriers of five risk alleles have an OR of 6.78. IRF5 and STAT4 are components of the type I IFN system, and our findings emphasize the importance of this system in the etiopathogenesis of primary SS.
Introduction
Primary Sjö gren's syndrome (SS) is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of the salivary and lacrimal glands, which results in dry mouth, xerostomia and dry eyes (keratoconjunctivitis sicca). In addition, primary SS patients can have extra glandular manifestations, with Raynaud's phenomenon, arthritis and skin vasculitis being the most common, and leucopenia and hypergammaglobulinemia are often seen. 1 Sera from approximately 75% of patients with SS display antinuclear antibodies, and approximately 70 and 40% have antibodies against the specific SS antigens A and B (SS-A, SS-B), respectively. The HLA-DRB1*03, DQB1*02 and DQA1*05 alleles are associated with the presence of autoantibodies against SS-A and SS-B, and with primary SS in Caucasians. The clinical and serological features of primary SS have similarities to those of systemic lupus erythematosus (SLE), and patients with primary SS can later develop SLE with secondary SS. Primary SS and SLE with secondary SS have a common genetic background, with a high frequency of the HLA-DRB1*0301 allele. 2 Early association studies of candidate genes outside the HLA-locus in primary SS have been small and have obtained conflicting results.
Recently, single nucleotide polymorphisms (SNPs) in two genes from the type I IFN system, the SNP rs2004640 in the interferon regulatory factor 5 (IRF5) gene on chromosome 7q32 and the SNP rs7574865 in the signal transducer and activator of transcription 4 (STAT4) gene on chromosome 2q32.3, were found to be associated also with primary SS. 3, 4 This is interesting as an activation of the type I interferon (IFN) system in patients with primary SS has been shown convincingly. Thus, IFN-a production 5 and the presence of plasmacytoid dendritic cells 6 in minor salivary gland biopsies have been shown. Gene expression profiling of minor salivary glands have shown upregulation of type I IFN-inducible genes, which is called an IFN signature. 6, 7 In addition, sera from primary SS patients together with material from apoptotic or necrotic cells induce IFN-a production in peripheral blood mononuclear cells in vitro, and this IFN-inducing ability of primary SS patient serum correlates with the presence of anti-SS-A/SS-B antibodies. 5 High serum IFN activity had also been shown in a proportion of anti-SS-A antibody-positive patients with primary SS or SLE. 8 An activation of the type I IFN system is a feature shared between patients with primary SS and patients with SLE, 9 and the observation that IRF5 and STAT4 associates to both diseases further links these two conditions to each other.
The type I IFN system consists of a group of cytokines, including IFN-a, the stimuli for IFN production, the professional IFN-producing cells (that is, plasmacytoid dendritic cells), the type I IFN receptor with its signaling pathways and the target cells for IFN action. In addition to the production of antiviral proteins, type I IFN action has several immunomodulatory effects, such as maturation of dendritic cells, activation of Th1 and Tc cells, as well as increased immunoglobulin production by B cells. 9 Stimuli for type I IFN production can be either exogenous (for example, viral DNA or RNA) or endogenous immune complexes consisting of nucleic acids and autoantibodies, which bind to FcgRIIa on plasmacytoid dendritic cells, followed by internalization and binding to toll-like receptors 7 and 9. 10 This process activates several transcription factors, including IRF5, which ultimately leads to transcription of type I IFN genes and other genes involved in cell-cycle regulation, apoptosis and a proinflammatory immune response.
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Interferon regulatory factor 5 transcription is also induced by type I IFN ligation of the IFN receptor, and thus IRF5 is involved both in type I IFN production and in its action.
STAT4 is a transcription factor activated by cytokines, including type I IFN, interleukin-12 and interleukin-23, the latter stimulating Th17 cells, which are important in the regulation of proinflammatory responses. After ligation of their corresponding receptors, STAT4 is phosphorylated and translocates to the nucleus, where it upregulates transcription of genes, including IFN-g and TNF-a, and mediates the development of activated Th1 cells. 12 Consequently, among other effects, both IRF5 and STAT4 are important mediators of type I IFN action.
Earlier we have conducted a comprehensive association analysis in SLE of 47 polymorphisms identified by complete sequence analysis of the IRF5 gene. 13 According to a Bayesian model selection analysis of association data from Swedish SLE patients and controls, two polymorphisms in the IRF5 gene emerged as major, independent risk factors for SLE. One of them is a previously unknown 5-bp insertion-deletion (CGGGG indel) polymorphism located 64 kb upstream of the first untranslated exon 1a of IRF5, where the risk allele carries four copies of a repeated CGGGG unit. This polymorphism accounts for the association signal observed for several SNPs in IRF5, including the SNP rs2004640. The Bayesian model averaging approach takes into account all possible combinations of associated alleles, and according to this analysis the evidence for the CGGGG indel alone as causal allele was strong, compared with a model in which the risk alleles of the CGGGG indel and of the SNP rs2004640 or any other of the correlated alleles would act in concert. 13 The other independent risk factor is the SNP rs10488631 located 5 kb downstream of IRF5. This SNP is in high linkage disequilibrium (LD) with several other SNPs located in the 3 0 -untranslated region and downstream of IRF5.
14 Recently we genotyped 53 SNPs in the STAT4 gene, which capture 91% of the genetic variation of STAT4. We identified a single common risk haplotype for SLE, which is tagged by either of two strongly linked SNPs, rs7582694 and rs10181656, which are in complete LD (r 2 ¼ 1.0) with the SNP rs7574865 first identified as risk factor for both SLE and rheumatoid arthritis (RA). 15 In the current study, we investigated the association of the two major independent IRF5 polymorphisms, the CGGGG indel and the SNP rs10488631 and the STAT4 SNP rs7582694 with primary SS, in a Swedish and Norwegian primary SS cohort, and determined the joint effects of these three polymorphisms on the risk for developing primary SS.
Results
We investigated the association of the IRF5 and STAT4 genes with primary SS by genotyping a CGGGG indel polymorphism in the promoter of IRF5 and the SNP rs10488631 in IRF5, and the SNP rs7582694 in STAT4 in a total of 368 well-characterized patients with primary SS, of whom 228 were from Sweden and 140 from Norway (Table 1) , and 563 Swedish and 148 Norwegian controls. These three polymorphisms were selected for the study on primary SS based on our results from comprehensive association studies of IRF5 and STAT4, in which these polymorphisms account for most of the association signals with SLE. 13, 16 Despite the low number of individuals in the Norwegian cohort, the CGGGG indel was significantly associated with primary SS and the IRF5 SNP rs10488631 showed a suggestive association with primary SS. In a metaanalysis of the data from the two cohorts, the significance of the association with primary SS was strengthened for all three polymorphisms. The CGGGG indel and the SNP rs10488631 in IRF5 define a risk haplotype carrying both risk alleles with a P-value of 9.57 Â 10 À5 and an odds ratio (OR) of 1.63 (95% CI 1.28-2.09) and a protective haplotype carrying the non-risk alleles with a P-value of 2.88 Â 10
À5 and an OR of 0.67 (95% CI 0.56-0.81) for primary SS (Table 3 ). The haplotypes formed by one risk allele and one non-risk allele of IRF5 are neutral, which is consistent with the independent effect on primary SS by these two polymorphisms.
The risk alleles of all three polymorphisms are the same in primary SS as in SLE, and they occur at similar allele frequencies in Swedish primary SS and SLE patients. The risk allele frequency for the CGGGG indel was 0.54 in our primary SS patients and 0.57 in the SLE patients (P ¼ 0.47), the risk allele frequency for the SNP rs10488631 was 0.19 in primary SS and 0.23 in SLE (P ¼ 0.21) and the SNP rs7582694 was 0.29 in primary SS and 0.33 in SLE patients (P ¼ 0.30) ( Table 2 and Sigurdsson et al.
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). The association signals for primary SS in the combined cohort were slightly stronger for the two polymorphisms in IRF5 with an OR of 1.49 (95% CI 1.24-1.79) for the CGGGG indel and an OR of 1.57 (95% CI 1.23-1.99) for the SNP rs10488631, compared with an OR of 1.41 (95% CI 1.14-1.73) for the SNP rs7582694 in STAT4 (Table 2) . Clinical information on the presence of antinuclear antibodies, anti-SS-A and anti-SS-B antibodies was available from 364 out of 368 (99%) patients (Table 1) . No correlation was found between the presence of any of these antibodies and the genotypes at the IRF5 or STAT4 polymorphisms (Supplementary Table 1) .
We also investigated the joint effect of the three polymorphisms in IRF5 and STAT4 on the risk for primary SS. Figure 1 shows the distribution of SS patients and controls in each group of individuals carrying the different number of risk alleles (0-5). A higher frequency of patients than controls carried more than two risk alleles and 4.2% of the patients carried five risk alleles compared with 0.9% of the controls. No individual in our cohort carried six risk alleles. The different combinations of risk alleles and their distribution in patients and controls are shown in Supplementary Table 2. According to an additive logistic regression model, the significance for the overall differences in risk allele count between patients and controls in these groups is very high, with a one-sided P-value of 2.5 Â 10
À9
. Figure 2 shows a plot of the OR for developing primary SS as a function of the number of risk alleles for primary SS, using the individuals with zero or one risk allele as a reference. The resulting straight line obtained when OR is plotted against the number of risk alleles shows that the risk for developing primary SS increases in an additive manner. For the carriers of two risk alleles, the OR is 1.43 (95% CI Table 2 Association analysis of three polymorphisms with primary Sjö gren's syndrome in the Swedish and Norwegian cohorts Unadjusted P-value for differences in allele frequencies between patients and controls.
c Combined P-value calculated using Cochran-Mantel Haenszel w 1.04-1.98), whereas carriers of five risk alleles have an OR of 6.78 (95% CI 2.65-17.32). The regression coefficient (r 2 ) for the line equals 0.9, indicating an excellent fit for the data. No evidence for dominance or interaction between the risk alleles was observed using multiple logistic regression analysis.
Discussion
Here we show an association of both IRF5 and STAT4 with primary SS, and show a strong additive effect of the same risk alleles of three major polymorphisms in IRF5 and STAT4 that have been identified in SLE. 16 The IRF5 and STAT4 genes are, according to two recently conducted genome-wide association studies, 17, 18 among the genes that display the strongest association with SLE. Polymorphisms in IRF5 and STAT4 have been reported in two independent studies to be associated with primary SS. 3, 4 In a study on IRF5 in the French population, four SNPs were genotyped and one of them, the SNP rs2004640, appeared to be associated with primary SS (P ¼ 0.04). 4 The SNP rs2004640 is in relatively high LD with the CGGGG indel (r 2 ¼ 0.67) (Supplementary Figure 1 ), which was found to be strongly associated with primary SS in our study. Both the SNP rs2004640 and the CGGGG indel are associated with SLE, and in a recent study we have shown that the CGGGG indel alone accounts for all the association signals from multiple linked SNPs in the 5 0 region, including the SNP rs2004640. 13 However, the current association data available for IRF5 in primary SS do not exclude the possibility that there could be differences between the association patterns in SLE and primary SS if a more comprehensive set of markers would be analyzed in a large set of primary SS samples.
The longer (4 Â CGGGG) risk allele of the CGGGG indel, which is located 64 bp upstream of the alternative exon 1a of IRF5, creates an additional binding site for the transcription factor SP1. 13 The 4 Â CGGGG allele drives increased expression of IRF5 transcripts containing exon 1a, as shown by a reporter gene assay. 13 These findings suggest a functional role for the CGGGG indel. A functional role has also been suggested for the SNP The risk alleles are the 4 Â CGGGG indel and the C-allele in the SNP rs10488631.
b Unadjusted P-value for differences in haplotype frequencies between patients and controls. IRF5 and STAT4 polymorphisms in primary SS G Nordmark et al rs2004640, which is located at the splice junction of the alternative exon 1b of IRF5. 14, 19 The risk allele of the SNP rs2004640 correlates with expression of exon 1b, but the functional importance of the SNP rs2004640 has been questioned, as exon 1b is expressed in peripheral blood mononuclear cells at a substantially lower level than transcripts containing exon 1a and the expression levels of IRF5 transcripts containing exon 1a are independent of the genotype of the SNP rs2004640. 20 Despite the strong statistical evidence in favor of the CGGGG as the main risk allele for SLE in this group of associated, correlated polymorphisms, we cannot exclude a functional role for the SNP rs2004640. It is possible that the alternatively spliced transcript caused by the risk allele of the SNP rs2004640 is expressed at a higher level in other tissues than peripheral blood mononuclear cells and may have a functional role.
Interestingly, the IRF5 SNP rs2070197, which is in high pair-wise LD with the SNP rs10488631 (r 2 X0.97) for which we observed a strong association with primary SS in our study, gave no association signal with primary SS in the French study 4 (Table 4 ). These discrepant results could be due to a limited power of the French study, which included fewer samples. The IRF5 SNP rs10488631 has been found to be strongly associated with SLE in multiple studies in Caucasians. 13, 14, 18 A recent study found that this SNP was not polymorphic in a Japanese population. 27 A strong association between the IRF5 SNP rs10488631 and RA was described in a subgroup of RA patients who lack antibodies against cyclic citrullinated peptides (anti-CCP negative RA) or are positive for the HLA shared epitope (SE), and a small subgroup that are both anti-CCP negative and SE positive. 26 The SE is known to correlate with anti-CCP positivity, and this apparent discrepancy needs further clarification as to whether SE-positive and anti-CCP-negative RA constitutes an unusual, small subgroup with specific susceptibility genes. The polymorphisms in the 5 0 -end of IRF5 have been clearly shown to be most strongly associated with anti-CCP-negative RA 26, 25 (Table 4 ). The SNP rs10488631, which is located 5 kb downstream of IRF5, is according to data from the HapMap project in almost perfect LD (r 2 X0.97), with the SNP rs2070197 located in the 3 0 -untranslated region of IRF5 and with several other SNPs distributed over a 100-kb region downstream of the IRF5 gene. This region contains the transportin 3 (TNPO3) gene. By statistical methods it is not possible to distinguish whether the association signal from these SNPs with primary SS, SLE and a subset of RA originates from the IRF5 or the TNPO3 gene. On the basis of bioinformatics data, no obvious functional role for any of these SNPs in the 3 0 end can be predicted.
It is interesting to note that when IRF5 polymorphisms from both groups have been investigated for their association with inflammatory bowel diseases and multiple sclerosis, association from only the group of polymorphisms defined by the CGGGG indel has been observed, 28, 29 whereas no association has been reported for the SNP rs10488631 or other perfectly linked SNPs (Table 4 ). These findings provide evidence for a more similar genetic background in the rheumatic diseases primary SS, SLE and the subset of RA patients who are anti-CCP negative, which differs from that in inflammatory bowel diseases and multiple sclerosis.
An association between autoimmune diseases and STAT4 was first shown in RA and SLE, 15 in which the SNP rs7574865 in intron 3 of STAT4 gave strong signals for association with an OR of 1.32 for RA and 1.55 for SLE, and this finding was later replicated in a cohort of primary SS patients with an OR of 1.46. 3 Here we show an association between the STAT4 SNP rs7582694 and primary SS with an OR of 1.41. The SNP rs7582694 genotyped in our study is in perfect LD (r 2 ¼ 1) with the previously identified SNP rs7574865, and therefore the results are fully comparable between studies. We found almost identical minor allele frequencies (MAF) in our cohort as in the previous study, 3 and confirmed the MAF among healthy controls of European ancestry to 0.22-0.23, whereas in an isolated population in Greece the MAF in controls was found to be 0.17 30 (Table 5) . Interestingly, the MAF in Korean RA patients and controls differ from RA patients of European ancestry but give the same OR for RA. 36 Recently, an association between STAT4 and inflammatory bowel diseases and type I diabetes has been shown, whereas there was no association with multiple sclerosis. 35, 37 A functional role is suggested for the risk haplotype of STAT4, which is tagged by the SNP rs7582694 by allele-specific differences in the expression of the risk haplotype in cells of mesenchymal origin. 16 Whereas STAT4 has been associated with rheumatic diseases in patients of Caucasian and Asian origin, polymorphisms in IRF5 have been associated with SLE in multiple ethnic populations, including Hispanics and African Americans. 23, 22, 24 This implies that both IRF5 and STAT4 and the type I IFN system are of importance in the development of autoimmune rheumatic diseases.
The genetic effect of IRF5 and STAT4 in rheumatic diseases seems to be strongest for SLE, followed by primary SS and RA according to OR. An activation of the type I IFN system has also most convincingly been shown in SLE. It is likely that some genes are of major importance for developing autoimmune diseases, whereas others determine the disease phenotype. The disease association of the risk alleles of IRF5 and STAT4 was independent of the autoantibody status of the primary SS patients in this study, as has previously been shown for IRF5. 4 However, the analysis done here does not fully exclude the possibility of a correlation between other SNPs in these two genes and autoantibody status. In conclusion, we show here for the first time an additive effect of the major risk alleles in IRF5 and STAT4 in primary SS and show the association between primary SS and polymorphisms in these genes. This further emphasizes the importance of the type I IFN system in the etiopathogenesis of primary SS. Future studies will assess the functional consequences of these genetic variations and their possible impact on disease phenotype.
Patients and methods
Patients and controls A total of 368 patients with primary SS and 711 controls were included in our study. The patients were selected from the rheumatology clinics at the Malmö (n ¼ 93), Linkö ping (n ¼ 66) and Uppsala (n ¼ 69) University Hospitals in Sweden and the rheumatology clinic at Haukeland University Hospital in Norway (n ¼ 140). All 38 and over 95% of them were Caucasians. Three out of 228 Swedish SS patients had an intermittent low positive titer for anti-double-stranded DNA antibodies, but none of them had a clinical diagnosis of SLE. None of the Norwegian patients displayed anti-double-stranded DNA antibodies. Patients with secondary SS were excluded from the study. The controls consisted of healthy blood donors from the same geographical areas as the patients (n ¼ 498) and of samples from the population-based EIRA (Epidemiological Investigation of Rheumatoid Arthritis) control cohort from Stockholm (n ¼ 213). Individuals with a known autoimmune disease are not accepted as blood donors, but the possibility that a person with a mild undiagnosed SS would be among the blood donors used as controls cannot be excluded. In the population-based EIRA control cohort, a genomewide scan with Illumina Human Hap300 39 reveals a relatively homogenous population with a genomic control l value of 1.05, which is evidence for a low degree of population admixture. Data on autoantibody profile were obtained from the patients' files. The characteristics of the patients are shown in Table 1 . All patients gave their informed consent and the study was approved by the relevant ethical committees in Uppsala for the Swedish cohort and in Bergen, Norway, for the Norwegian cohort.
Genotyping
Three polymorphisms were genotyped, a 5-bp insertiondeletion (CGGGG indel) polymorphism in IRF5 and the SNP rs10488631 in IRF5 and the SNP rs7582694 in STAT4.
The SNPs were genotyped in all patient samples (n ¼ 368) and the Norwegian controls (n ¼ 148), using a homogeneous minisequencing assay with fluorescence polarization detection (FP-TDI) (Analyst AD, Molecular Devices, Sunnyvale, CA, USA). 40 The genotyping success rate for the samples was 97.1% for the SNP rs10488631 and 98.4% for the SNP rs7582694. The reproducibility of the genotyping was 100% as estimated from genotype comparison between repeated assays for 8% of the patients. The SNPs rs10488631 and rs7582694 were genotyped in the Swedish controls (n ¼ 563) using the GoldenGate assay from Illumina Inc. (San Diego, CA, USA) 41 as described earlier. 13, 16 The sample success rate was 95.2% for the SNP rs10488631 and 95.6% for the SNP rs7582694. The reproducibility of genotyping was 100% for the two SNPs as estimated from a duplicate genotyping of 2.5% of the samples. In all SS patients and controls the CGGGG indel was amplified as a 100/ 105-bp PCR fragment, and the amplified fragments were separated on 4% MetaPhor high-resolution agarose gels (Cambrex Bio Science Rockland Inc., Rockland, ME, USA) and visualized by ethidium bromide staining. The PCR conditions are provided in Supplementary Table 3 . The success rate for genotyping the CGGGG indel was 98%, and the reproducibility of the genotyping was 100% according to repeated genotyping of 48% of the patients. The genotype frequencies of the polymorphisms fulfilled the criteria of Hardy-Weinberg equilibrium in the control samples (P40.01). In the analysis of joint effects of the three polymorphisms, only samples with successfully called genotypes for each of the polymorphisms were included. The sequences of the PCR and extension 
Statistical analysis
Allele counts and genotype frequencies were compared between patient and controls by chi-square using the Haploview v 4.0 software. Cochran-Mantel Haenszel chi-square test was used to combine P-values and calculating OR from the Swedish and Norwegian cohorts. Before performing the combined analysis of the two independent cohorts, lack of heterogeneity in the populations was confirmed by logistic regression analysis. Linear regression analysis was used to determine the joint effects of the risk alleles of the three polymorphisms. Interactions between the polymorphisms and the overall significance of the differences in risk allele count between patients and controls were tested by a logistic regression model in the statistical software package R (v 2.2.1). Given that the associated polymorphisms have earlier been established as risk factors for SLE, we performed a one-sided test.
